Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Int.biotech. (IBT) Share Price

Price 850.00p on 27-03-2026 at 19:40:07
Change -10.00p -1.16%
Buy 862.00p
Sell 850.00p
Last Trade: Unknown 0.00 at 864.00p
Day's Volume: 57,711
Last Close: 850.00p
Open: 874.00p
ISIN: GB0004559349
Day's Range 850.00p - 874.00p
52wk Range: 480.00p - 1,000.00p
Market Capitalisation: £271.17m
VWAP: 867.75314p
Shares in Issue: 31.90m

Int.biotech. (IBT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 0 864.00p SI Trade
16:26:25 - 27-Mar-26
Sell* 104 852.00p Automatic Execution
16:26:25 - 27-Mar-26
Sell* 406 856.00p Automatic Execution
16:26:25 - 27-Mar-26
Sell* 36 856.00p Automatic Execution
16:26:25 - 27-Mar-26
Sell* 54 856.00p Automatic Execution
16:26:25 - 27-Mar-26
Sell* 53 858.00p Automatic Execution
16:26:25 - 27-Mar-26
Sell* 750 858.00p Automatic Execution
16:26:25 - 27-Mar-26
Buy* 120 864.00p SI Trade
16:25:42 - 27-Mar-26
Unknown* 0 864.00p SI Trade
16:25:03 - 27-Mar-26
Unknown* 0 866.00p SI Trade
15:46:31 - 27-Mar-26
See more Int.biotech. trades

Int.biotech. (IBT) Share Price History

Time period:
to
Date Open High Low Close Volume
27th Mar 2026 (Fri) 874.00 874.00 850.00 850.00 57,711
26th Mar 2026 (Thu) 876.00 876.00 860.00 860.00 29,452
25th Mar 2026 (Wed) 858.00 872.00 848.00 868.00 56,495
24th Mar 2026 (Tue) 860.00 860.00 842.00 842.00 31,017
23rd Mar 2026 (Mon) 866.00 874.00 860.00 860.00 66,629
20th Mar 2026 (Fri) 872.00 890.00 870.00 878.00 32,642
19th Mar 2026 (Thu) 876.00 876.00 876.00 876.00 40,072
18th Mar 2026 (Wed) 900.00 900.00 880.00 880.00 66,574
17th Mar 2026 (Tue) 906.00 906.00 898.00 898.00 64,661
16th Mar 2026 (Mon) 894.00 908.00 894.00 908.00 32,066
13th Mar 2026 (Fri) 906.00 906.00 892.00 892.00 31,676
12th Mar 2026 (Thu) 922.00 922.00 900.00 900.00 65,930
11th Mar 2026 (Wed) 922.00 936.00 920.00 934.00 26,311
10th Mar 2026 (Tue) 914.00 932.00 914.00 924.00 61,182
9th Mar 2026 (Mon) 882.00 916.00 882.00 906.00 77,998
6th Mar 2026 (Fri) 892.00 908.00 892.00 908.00 50,103
5th Mar 2026 (Thu) 908.00 912.00 904.00 910.00 83,795
4th Mar 2026 (Wed) 902.00 910.00 888.00 910.00 135,474
3rd Mar 2026 (Tue) 900.00 902.00 886.00 902.00 61,067
2nd Mar 2026 (Mon) 910.00 912.00 904.00 904.00 45,890
See more Int.biotech. price history

Int.biotech. (IBT) Regulatory News

Date Source Headline
27th Mar 2026 11:51 am RNS Net Asset Value(s)
26th Mar 2026 11:56 am RNS Net Asset Value(s)
25th Mar 2026 2:43 pm RNS-R IBT portfolio company Terns acquired by Merck
25th Mar 2026 12:01 pm RNS Net Asset Value(s)
24th Mar 2026 11:54 am RNS Net Asset Value(s)
23rd Mar 2026 11:56 am RNS Net Asset Value(s)
20th Mar 2026 11:54 am RNS Net Asset Value(s)
19th Mar 2026 11:54 am RNS Net Asset Value(s)
18th Mar 2026 11:45 am RNS Net Asset Value(s)
17th Mar 2026 11:28 am RNS Net Asset Value(s)
See more Int.biotech. regulatory news

Int.biotech. (IBT) Share News

Servier acquires International Biotech's Day One for USD2.5 billion

9th Mar 2026 09:30

(Alliance News) - International Biotechnology Trust PLC on Monday said its portfolio company Day One Biopharmaceuticals Inc has agreed to be acquired by Servier in a USD2.5 billion cash deal. Read More

UK dividends calendar - next 7 days

16th Jan 2026 15:52

Read More

UK dividends calendar - next 7 days

22nd Dec 2025 14:43

Read More

International Biotechnology beats benchmark with 0.7% NAV gain

6th Nov 2025 19:17

(Alliance News) - International Biotechnology Trust PLC on Thursday said its portfolio continued to outperform the sector benchmark as the company reported full-year results. Read More

IN BRIEF: International Biotechnology Trust notes Novo to buy Akero

9th Oct 2025 15:40

International Biotechnology Trust PLC - investor in biotech and life science companies - Notes portfolio firm Akero Therapeutics Inc as agreed to be taken over by Novo Nordisk AS in a deal worth up to EUR5.2 billion. Novo Nordisk will pay an initial USD54 per share, with a contingent portion of the deal worth USD6 per share. The Bagsvaerd, Denmark-based pharmaceuticals company will pay an initial EUR4.7 billion to buy the firm, and a potential additional payment of EUR500 million, hinging on US regulatory approval for key Akero treatment Efruxifermin. The deal adds Akero's Efruxifermin to Novo Nordisk's portfolio. The asset is aimed at treating metabolic dysfunction-associated steatohepatitis, a disease caused by fat buildup in the liver. Read More

See more Int.biotech. news
FTSE 100 Latest
Value9,967.35
Change-4.82

Login to your account

Forgot Password?

Not Registered